28368473|t|Targeting MYC as a therapeutic intervention for anaplastic thyroid cancer
28368473|a|Recent studies showed that transcription of the MYC gene is driven by interaction of bromodomain and extraterminal domain (BET) proteins with acetylated histones on chromatin. A potent inhibitor, JQ1, which effectively disrupts the interaction of BET proteins with acetylated histones, preferentially suppresses transcription of the MYC gene. We recently reported that JQ1 decreased thyroid tumor growth and improved survival in a mouse model of anaplastic thyroid cancer (ATC) by targeting MYC transcription. It remains to be elucidated on the role of MYC in human ATC and whether JQ1 could effectively target MYC as a novel treatment modality. To understand underlying molecular mechanisms of JQ1's effects on human ATC, we evaluated the efficacy of JQ1 in human ATC cell lines and xenograft models. We determined the effects of JQ1 on proliferation and invasion in cell lines and xenograft tumors. We identified key regulators critical for JQ1 -affected proliferation and invasion of tumor cells. JQ1 markedly inhibited proliferation of 4 ATC cell lines by suppression of MYC and elevation of p21and p27 to decrease phosphorylated Rb to delay cell cycle progression from the G0/G1 phase to the S phase. JQ1 blocked cell invasion by attenuating epithelial mesenchymal transition signals. These cell-based studies were further confirmed in xenograft studies in that the size and rate of tumor growth was inhibited by JQ1 via inhibition of p21-Cyclin/CDK-Rb-E2F signaling. These results suggest targeting MYC protein could be a potential novel treatment modality for human ATC for which effective treatment options are limited.
28368473	0	9	Targeting	T169	C1521840
28368473	10	13	MYC	T028	C0086661
28368473	19	43	therapeutic intervention	T061	C0808232
28368473	48	73	anaplastic thyroid cancer	T191	C0238461
28368473	74	88	Recent studies	T062	C2603343
28368473	101	114	transcription	T045	C0040649
28368473	122	130	MYC gene	T028	C0086661
28368473	144	155	interaction	T169	C1704675
28368473	159	210	bromodomain and extraterminal domain (BET) proteins	T116,T123	C0033684
28368473	216	235	acetylated histones	T044	C2753333
28368473	239	248	chromatin	T116	C0008546
28368473	252	268	potent inhibitor	T121	C1254351
28368473	270	273	JQ1	T109,T121	C3252362
28368473	293	301	disrupts	T080	C0332454
28368473	306	317	interaction	T169	C1704675
28368473	321	333	BET proteins	T116,T123	C0033684
28368473	339	358	acetylated histones	T044	C2753333
28368473	375	385	suppresses	T169	C1260953
28368473	386	399	transcription	T045	C0040649
28368473	407	415	MYC gene	T028	C0086661
28368473	420	437	recently reported	T058	C0700287
28368473	443	446	JQ1	T109,T121	C3252362
28368473	447	456	decreased	T081	C0205216
28368473	457	470	thyroid tumor	T191	C0040136
28368473	471	477	growth	T191	C0598934
28368473	482	490	improved	T033	C0184511
28368473	491	499	survival	T169	C0220921
28368473	505	516	mouse model	T050	C2986594
28368473	520	545	anaplastic thyroid cancer	T191	C0238461
28368473	547	550	ATC	T191	C0238461
28368473	565	568	MYC	T028	C0086661
28368473	569	582	transcription	T045	C0040649
28368473	627	639	MYC in human	T116,T123	C1454487
28368473	640	643	ATC	T191	C0238461
28368473	656	659	JQ1	T080	C1999216
28368473	666	677	effectively	T080	C1704419
28368473	685	688	MYC	T116,T123	C1454487
28368473	694	718	novel treatment modality	T061	C0009429
28368473	745	765	molecular mechanisms	T044	C3537153
28368473	769	774	JQ1's	T080	C1999216
28368473	775	782	effects	T080	C1280500
28368473	786	791	human	T016	C0086418
28368473	792	795	ATC	T191	C0238461
28368473	800	809	evaluated	T058	C0220825
28368473	814	822	efficacy	T080	C1280519
28368473	826	829	JQ1	T080	C1999216
28368473	833	838	human	T016	C0086418
28368473	839	842	ATC	T191	C0238461
28368473	843	853	cell lines	T025	C0085983
28368473	858	874	xenograft models	T050	C1520166
28368473	894	901	effects	T080	C1280500
28368473	905	908	JQ1	T080	C1999216
28368473	912	925	proliferation	T169	C1514485
28368473	930	938	invasion	T033	C1269955
28368473	942	952	cell lines	T025	C0085983
28368473	957	966	xenograft	T061	C0520484
28368473	967	973	tumors	T191	C0027651
28368473	978	988	identified	T080	C0205396
28368473	989	1003	key regulators	T077	C1704735
28368473	1004	1012	critical	T080	C1511545
28368473	1017	1020	JQ1	T080	C1999216
28368473	1031	1044	proliferation	T169	C1514485
28368473	1049	1072	invasion of tumor cells	T033	C1269955
28368473	1074	1077	JQ1	T080	C1999216
28368473	1087	1096	inhibited	T080	C0311403
28368473	1097	1110	proliferation	T169	C1514485
28368473	1116	1119	ATC	T191	C0238461
28368473	1120	1130	cell lines	T025	C0085983
28368473	1134	1145	suppression	T169	C1260953
28368473	1149	1152	MYC	T116,T123	C1454487
28368473	1157	1166	elevation	T082	C0702240
28368473	1170	1180	p21and p27	T116	C0598086
28368473	1184	1192	decrease	T081	C0547047
28368473	1193	1207	phosphorylated	T044	C1158886
28368473	1208	1210	Rb	T116,T123	C0080113
28368473	1214	1230	delay cell cycle	T043	C0007586
28368473	1231	1242	progression	T169	C0449258
28368473	1252	1263	G0/G1 phase	T079	C0205390
28368473	1271	1278	S phase	T079	C0080129
28368473	1280	1283	JQ1	T080	C1999216
28368473	1284	1291	blocked	T169	C0332206
28368473	1292	1305	cell invasion	T033	C1269955
28368473	1321	1362	epithelial mesenchymal transition signals	T043	C1523298
28368473	1370	1388	cell-based studies	T062	C2603343
28368473	1402	1411	confirmed	T033	C0750484
28368473	1415	1424	xenograft	T061	C0520484
28368473	1425	1432	studies	T062	C2603343
28368473	1445	1449	size	T082	C0456389
28368473	1454	1458	rate	T081	C1521828
28368473	1462	1474	tumor growth	T191	C0598934
28368473	1479	1488	inhibited	T080	C0311403
28368473	1492	1495	JQ1	T080	C1999216
28368473	1500	1510	inhibition	T052	C3463820
28368473	1514	1545	p21-Cyclin/CDK-Rb-E2F signaling	T044	C0037080
28368473	1553	1560	results	T169	C1274040
28368473	1579	1590	MYC protein	T116,T123	C1454487
28368473	1602	1611	potential	T080	C3245505
28368473	1612	1636	novel treatment modality	T061	C0009429
28368473	1641	1646	human	T016	C0086418
28368473	1647	1650	ATC	T191	C0238461
28368473	1661	1670	effective	T080	C1704419
28368473	1671	1688	treatment options	T061	C0683525
28368473	1693	1700	limited	T169	C0439801